Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality

Published:2020-01-01 Issue:1 Volume:7 Page:1807682
ISSN:2001-8525
Container-title:European Clinical Respiratory Journal
language:en
Short-container-title:European Clinical Respiratory Journal

Author:

Hyldgaard Charlotte¹^ORCID,Møller Janne²^ORCID,Bendstrup Elisabeth²^ORCID

Affiliation:

1. Diagnostic Center, University Research Clinic for Innovative Patient Pathways, Silkeborg Regional Hospital, Silkeborg, Denmark

2. Center for Rare Lung Diseases, Department of Respiratory Diseases and Allergy, Aarhus University Hospital, Aarhus, Denmark

Publisher

Informa UK Limited

Subject

Pulmonary and Respiratory Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/20018525.2020.1807682

Reference27 articles.

1. An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management

2. Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry

3. Management of patients with idiopathic pulmonary fibrosis in clinical practice: the INSIGHTS-IPF registry

4. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis

5. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Protective effects of microbial biosurfactants produced by Bacillus halotolerans and Candida parapsilosis on bleomycin-induced pulmonary fibrosis in mice: Impact of antioxidant, anti-inflammatory and anti-fibrotic properties via TGF-β1/Smad-3 pathway and miRNA-326;Toxicology and Applied Pharmacology;2024-05

2. [ ⁶⁴ Cu]Cu-PEG-FUD peptide for noninvasive and sensitive detection of murine pulmonary fibrosis;Science Advances;2024-04-12

3. Idiopathic Pulmonary Fibrosis: Where do We Stand and How Far to Go?;Discovery Medicine;2024

4. Non-peptidic immunoproteasome β5i-selective inhibitor as potential treatment for idiopathic pulmonary fibrosis: Virtual screening, hit evolution and lead identification;European Journal of Medicinal Chemistry;2023-12

5. Contributing factor for the pirfenidone dose reduction in patients with idiopathic interstitial pneumonia in real-world settings—A dose-specific analysis;2023-06-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3